Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
Retrieved on:
星期四, 十一月 2, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, SLE, PSF, FDA, Insurance, American College, EGFR, U.S.–Canada Team Tournament (Go), Conversation, SG, EDGAR, SEDAR, American Society of Nephrology, AURORA, Nephrology, Lupus, Persistent environment, EC, Glomerular filtration rate, R, Society, Arthritis & Rheumatology, Bank statement, Growth, Risk, Marketing, Webcast, Analysis, Healthcare Improvement Scotland, American College of Rheumatology, Safety, LN, Investment, Management, Patient, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Rheumatology, Cryptocurrency, Pharmaceutical industry, Rare-earth element, Aurinia
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.
Key Points:
- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.
- Total net revenue was $54.5 million for the three months ended September 30, 2023 and $55.8 million for the same period in 2022.
- Financial Results for the Three and Nine Months Ended September 30, 2023
Total net revenue was $54.5 million and $55.8 million for the three months ended September 30, 2023 and September 30, 2022, respectively. - Aurinia will host a conference call and webcast to discuss the quarter ended September 30, 2023 financial results today, Thursday, November 2, 2023 at 8:30 a.m.